Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 6,700.4 | 6,403.5 | 6,530.6 | 6,950.2 | 12,552.9 | 15,056.9 | 9,199.6 | 11,471.9 |
| Revenue growth | 4.6% | -1.9% | -6.0% | -44.6% | -16.6% | 63.7% | -19.8% | 44.4% |
| Cost of goods sold | 166.2 | 128.4 | 116.7 | 5,882.7 | 9,954.4 | 12,524.6 | 0.0 | 9,975.1 |
| Gross profit | 6,534.2 | 6,275.1 | 6,413.9 | 1,067.5 | 2,598.5 | 2,532.3 | 9,199.6 | 1,496.8 |
| Gross margin | 97.5% | 98.0% | 98.2% | 15.4% | 20.7% | 16.8% | 100.0% | 13.0% |
| Selling, general and administrative | 616.8 | 644.9 | 724.1 | 795.7 | 1,140.6 | 1,060.9 | 572.6 | 689.6 |
| Research and development | 67.0 | 78.4 | 75.3 | 149.5 | 189.2 | 212.9 | 105.4 | 95.5 |
| EBITA | 180.3 | 317.2 | 30.4 | 286.8 | 1,243.3 | 1,264.9 | 934.2 | 786.1 |
| EBITA margin | 2.7% | 5.0% | 0.5% | 4.1% | 9.9% | 8.4% | 10.2% | 6.9% |
| Amortization of intangibles | | | | 104.7 | 182.6 | 244.5 | 17.5 | 23.4 |
| EBIT | 180.3 | 317.2 | 30.4 | 182.1 | 1,060.7 | 1,020.4 | 916.7 | 762.7 |
| EBIT margin | 2.7% | 5.0% | 0.5% | 2.6% | 8.4% | 6.8% | 10.0% | 6.6% |
| Pre-tax income | 68.9 | 198.1 | -3,498.7 | -2,571.1 | -1,488.1 | 679.7 | 551.4 | 150.5 |
| Income taxes | 105.4 | 111.1 | 19.4 | 79.0 | 422.7 | 545.5 | 180.3 | 136.5 |
| Tax rate | 153.0% | 56.1% | | | | 80.3% | 32.7% | 90.7% |
| Earnings from continuing ops | 8.8 | 159.6 | -3,798.3 | -2,888.1 | -1,921.6 | 113.3 | 393.3 | 14.4 |
| Earnings from discontinued ops | -45.3 | -72.6 | 280.2 | 238.0 | | | | |
| Net income | -36.5 | 87.0 | -3,518.1 | -2,650.1 | -1,921.6 | 113.3 | 393.3 | 14.4 |
| Net margin | -0.5% | 1.4% | -53.9% | -38.1% | -15.3% | 0.8% | 4.3% | 0.1% |
| |
| Diluted EPS | $0.02 | $0.35 | ($8.47) | ($6.45) | ($4.20) | $0.24 | $3.14 | $0.11 |
| Shares outstanding (diluted) | 449.5 | 454.6 | 448.7 | 448.0 | 458.0 | 468.3 | 125.1 | 127.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|